Companies plan to file for full marketing approval to EMA and FDA in 2020 MOUNTAIN VIEW, Calif. and ZURICH, 24 January, 2019 – ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma...

Re-analysis of the PIVOTAL data by the investigators has revealed that proactive, high-dose Venofer® compared to reactive, low-dose Venofer® resulted in: Superiority and statistically...

Vifor Pharma Group is pleased to announce the appointment of Patrick Treanor as President of Relypsa on a permanent basis. He is also appointed to the Executive Committee of Vifor Pharma Group...

This year’s Iron Deficiency Day (26 November 2018) aims to raise awareness of the serious public health problems posed by iron deficiency and iron deficiency anaemia and highlight the negative...

PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF IV IRON DOSING STRATEGY PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS IRON DOSING STRATEGY ALLOWING HIGHER FERRITIN...